Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Machine Learning Blood Test May Allow Earlier Detection of Lung and Other Cancers

By LabMedica International staff writers
Posted on 01 Aug 2023
Print article
Image: Schematic of GEMINI approach for cancer detection (Photo courtesy of BioScience Communications)
Image: Schematic of GEMINI approach for cancer detection (Photo courtesy of BioScience Communications)

A unique blood testing technology currently under development that combines genome-wide sequencing of single molecules of DNA released by tumors with machine learning could enable earlier detection of lung and other cancers.

Researchers at the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA) are developing GEMINI (Genome-wide Mutational Incidence for Non-Invasive Detection of Cancer), a test that searches for DNA alterations across the genome. After the collection of a blood sample from individuals at risk of developing cancer, cell-free DNA (cfDNA) released by tumors is extracted from the plasma and sequenced using cost-effective whole-genome sequencing. Individual DNA molecules are then analyzed for sequence alterations in order to obtain mutation profiles across the genome. Utilizing a machine learning model trained to distinguish cancerous from non-cancerous mutation frequencies in various genome regions, the system can identify individuals with cancer. The model generates a score between 0 to 1, with higher scores indicating a greater likelihood of cancer.

The development of GEMINI involved the examination of whole-genome sequences from 2,511 individuals with 25 different cancer types, as part of the Pan-Cancer Analysis of Whole Genomes study. This led to the identification of distinct mutation frequencies across the genome in various tumor types, such as lung cancers, which had an average of 52,209 somatic mutations per genome. High-frequency mutation regions were found to be comparable between tumor tissue and blood-derived cfDNA in patients with lung cancer, melanoma, or B cell non-Hodgkin lymphoma.

Laboratory testing with GEMINI demonstrated promising results, with the detection of over 90% of lung cancers, including early-stage I and II disease, when combined with computerized tomography imaging. Its potential was further demonstrated in a study with seven participants without detectable tumors at the time of blood collection, who later received a lung cancer diagnosis. The median GEMINI score of this group was 0.78, higher than individuals without cancer. Six participants who tested positive using GEMINI were later diagnosed with lung cancer from 231 to 1,868 days after samples were obtained, indicating that abnormalities in cfDNA mutation profiles can be detected years ahead of standard diagnoses. Further experiments also found GEMINI capable of differentiating between subtypes of lung cancers, detecting early liver cancers, and monitoring patients' response to lung cancer treatment.

“This study shows for the first time that a test like GEMINI, incorporating genome-wide mutation profiles from single molecules of cfDNA, in combination with other cancer detection approaches, may be used for early detection of cancers, as well as for monitoring patients during therapy,” said senior study author Victor Velculescu, M.D., Ph.D., professor of oncology and co-director of the cancer genetics and epigenetics program at the Kimmel Cancer Center.

Related Links:
Johns Hopkins Kimmel Cancer Center

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.